Atlas Trials

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Clinical trial NCT04948034 · UNKNOWN

Trial details

NCT number
NCT04948034
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Colorectal Cancer
Start date
2021-08-23
Primary completion
2022-12-31
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.